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Background: Current consensus does not support the use of a universal booster of hepatitis B virus (HBV) vaccine
because there is an anamnestic response in almost all children 15 years after universal infant HBV vaccination. We
aimed to provide a booster strategy among adolescents as a result of their changes in lifestyle and sexual activity.
Methods: This study comprised a series of cross-sectional serological surveys of HBV markers in four age groups
between 2004 and 2012. The seropositivity rates of hepatitis B surface antigen (HBsAg) and its reciprocal antibody
(anti-HBs) for each age group were collected. There were two parts to this study; age-specific HBV seroepidemiology
and subgroup analysis, including effects of different vaccine types, booster response for immunogenicity at 15 years of
age, and longitudinal follow-up to identify possible additional protection by HBV booster.
Results: Within the study period, data on serum anti-HBs and HBsAg in a total of 6950 students from four age groups
were collected. The overall anti-HBs and HBsAg seropositivity rates were 44.3% and 1.2%, respectively. The anti-HBs
seropositivity rate in the plasma-derived subgroup was significantly higher in both 15- and 18-year age groups.
Overall response rate in the double-seronegative recipients at 15 years of age was 92.5% at 6 weeks following one
recombinant HBV booster dose. Among the 24 recipients showing anti-HBs seroconversion at 6 weeks after booster,
seven subjects (29.2%) had lost their anti-HBs seropositivity again within 3 years. Increased seropositivity rates and titers
of anti-HBs did not provide additional protective effects among subjects comprehensively vaccinated against HBV
in infancy.
Conclusions: HBV booster strategy at 15 years of age was the main contributor to the unique age-related
phenomenon of anti-HBs seropositivity rate and titer. No increase in HBsAg seropositivity rates within different age
groups was observed. Vaccination with plasma-derived HBV vaccines in infancy provided higher anti-HBs seropositivity
at 15–18 years of age. Overall booster response rate was 92.5% and indicated that intact immunogenicity persisted at
least 15 years after primary HBV vaccination in infancy. Booster vaccination of HBV did not confer additional protection
against HBsAg carriage in our study.
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The world’s first nationwide hepatitis B virus (HBV) infant
vaccination program was launched in Taiwan in July 1984,
starting with newborns of highly infectious mothers and
expanding to all newborns in July 1986 [1]. Prior to July
1992, infants were given four doses of plasma-derived vac-
cine at birth, 1, 2, and 12 months of age. After July 1992,
three doses of recombinant vaccine were administered at
the age of less than 1 week, 1 month, 6 months [2]. The
protective cut-off level was set at ≥10 mIU/mL for anti-
body to hepatitis B surface antigen (anti-HBs) based on
vaccine efficacy studies [3]. Over the past 20 years, the
hepatitis B surface antigen (HBsAg) seropositivity rate has
decreased from 9.8% in 1984 to 0.6% in 2004 among
people younger than 20 years of age in Taipei, Taiwan
[4-7]. Despite the success of the universal infant hepatitis
B (HB) vaccination program, chronic HBV infection and
hepatocellular carcinoma were not eliminated in children
in Taiwan. Among the children who initially responded to
the primary three-dose vaccination series, 15–50% de-
monstrate a low or undetectable anti-HBs level 5–15 years
after primary vaccination [8]. Although perinatal hepatitis
B virus transmission is still the main cause for vaccine
failure [2], horizontal and breakthrough infection may also
occur after waning or eventual loss of vaccine protective-
ness in older children, especially with changes in lifestyle
and sexual activity [9]. Currently, a booster of HB vaccin-
ation is not recommended for the general healthy popula-
tion after primary immunization because of the absence of
increased HBsAg seropositivity at different ages (<20 years
of age), which implies that there is no increased risk of
persistent HBV infection with aging [7]. Over the years,
the role of the anamnestic response, indicating immune
memory to HBsAg, was confirmed after anti-HBs levels
had decreased to below the seroprotective level. However,
a large-scale study provided evidence that an anamnestic
anti-HBs response was absent in 10.1% of 15- to 18-year-
old individuals in Taiwan, a country that had high ende-
micity of HBV [10].
In this report, we describe two parts of the present
study; age-specific HBV seroepidemiology and subgroup
analysis including effects of different vaccine types, im-
munogenicity response to booster at 15 years of age, and
longitudinal follow-up to assess possible additional pro-
tection by HBV booster.
Methods
Vaccination program in Taiwan
The nationwide HBV infant vaccination program in
Taiwan began with vaccination of newborns of highly
infectious mothers in July 1984 and then expanded to all
newborns in July 1986 [1]. Before July 1992, four doses
(5 μg/dose) of plasma-derived vaccine were given at
birth, 1, 2, and 12 months of age. After July 1992, threedoses of recombinant vaccine were given at the age of
less than 1 week, 1 month, and 6 months [2]. After July
1991 (birth cohort 1986), all newly enrolled elementary
school first graders were required to provide their vac-
cination cards for mandatory check-up, and those chil-
dren with incomplete vaccination records were given
catch-up HBV vaccination before enrolment.
Study population
This was a retrospective cross-sectional study composed
of serological surveys of HBV markers between 2004
and 2012 from newly enrolled students of the Tzu-Chi
University-affiliated education system, including ele-
mentary school (birth cohort 1998–2006), junior high
(birth cohort 1992–1994), senior high (birth cohort
1989–1997) schools, and university (birth cohort 1986–
1994) in Eastern Taiwan. A flow chart indicating our
study design is depicted in Figure 1. An approval cer-
tificate for this study was also issued from the Research
Ethics Committee of Hualien Tzu Chi Hospital, Buddhist
Tzu Chi Medical Foundation (REC No.: IRB101–125). A
total of 16,110 records including anti-HBs or HBsAg
were included in our database. We excluded subjects
without records of paired HBV markers (anti-HBs/
HBsAg) and those who were born before January 1st
1987, leaving a total of 6950 subjects in the epidemio-
logical study. We hypothesized that all of our subjects
received HBV vaccination within about 6 months fol-
lowing the introduction of the new vaccination policy at
that time. Based on the statistical records of Taiwan
National Immunization Information System (NIIS), the
immunization coverage rates of complete HBV vaccin-
ation were 88.8–97.7% (birth cohort 1984–2013), and
the complete rate of HBV vaccination among elemen-
tary school enrollments was above 99% after the 1997
birth cohort [11,12]. Written consent forms that were
provided by the Hualien County Government Education
Bureau were obtained from the students’ parents or
guardians upon school enrollment. The consent form
informed parents/guardians that these examinations
were non-intrusive with minimum risk and students or
parent/guardians were free to withdraw from any exa-
mination item at any time.
Epidemiological study
There were four groups of enrolled students: first
graders in elementary school (age 6 years), junior and
senior high school students (age 12 years and age
15 years) and freshmen at university (age 18 years).
Blood samples were collected from each student as part
of their health examination during the first semester of
their enrollment. The rates of anti-HBs and HBsAg
seropositivity among each group were collected and the
data spanning all 9 years were analyzed. In addition to
Figure 1 Flow chart of study design.
Chang et al. BMC Public Health 2014, 14:991 Page 3 of 11
http://www.biomedcentral.com/1471-2458/14/991qualitative anti-HBs data, anti-HBs serum titers were
available after 2007 for all school stages in our educa-
tion system. The rates of anti-HBs and HBsAg seropo-
sitivity, along with other demographic characteristics
such as gender, age, and median titers of anti-HBs were
also compared among different age groups. In the
12-year age group, only data from the school years
2004–2006 were available in our study. Therefore, we
also investigated whether there were any differences in
demographic characteristics within different time spans
such as 2004–2006 versus 2004–2012. There were no
data for anti-HBc available within our database. There-
fore, prevalence rates of natural infection could not be
estimated in our study.Subgroup analysis
Comparison of HBV markers by different vaccine types
In our study subjects, we noted some were vaccinated
with a plasma-derived HBV vaccine and others received
recombinant HBV vaccine in infancy, based on their birth
cohort. Subjects born before July 1992 received four doses
of plasma-derived vaccine (Hevac B; Pasteur-Merieux, or
its equivalent derivative); others, who were born after July
1992, received recombinant HBV vaccines (5 μg/dose of
Recombivax [Merck] or 20 μg/dose of Engerix [GSK]) [1].
Therefore, we selected subjects by their birth cohort,
grouping them as either plasma-derived or recombinant
vaccine recipients. In the 15-year age group, subjects from
birth cohorts 1989–1991 and 1993–1997 were grouped as
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the 18-year age group, subjects from birth cohorts 1987–
1991 and 1993–1994 were defined as plasma-derived and
recombinant groups, accordingly. We compared the sero-
prevalence of anti-HBs and HBsAg following administra-
tion of the different vaccine types in these two age groups.
Immunogenicity response in booster recipients at 15 years
of age
In our database, subjects in birth cohort 1992–1997
demonstrating double seronegativity for anti-HBs and
HBsAg in the 15-year age group were recommended to
receive one booster dose of recombinant HBV vaccine
(20 μg/dose). One booster dose was to be administered
in their school clinic on the same day under the supervi-
sion of the family physician. Post-booster blood sam-
pling for anti-HBs titers were also performed on the
same day in the school clinic an average of 6 weeks (range
35–50 days) after their booster date. The response rate to
one booster dose of HBV vaccine was defined as the pro-
portion of booster recipients whose post-booster titer was
≥10 mIU/mL. The overall and annual anti-HBs seroposi-
tivity rates after one booster dose of HBV vaccine were
also calculated. Anti-HBs seropositivity rates after one
booster dose were defined by the following equation:
Post‐booster anti‐HBs seropositive rate ¼
pre‐booster anti‐HBs seropositive rate
þ pre‐booster anti‐HBs seronegative rateð Þ
 booster rateð Þ  response rateð Þ
This equation was modified from the formula by Wu
et al. [13]. In their study, the overall anti-HBs seroposi-
tive rate, designated as PRT, after a booster dose of HB
vaccine was approximated by the following formula:
PRT ¼ PR1 þ 1‐PR1ð Þ x PR2;
where PR1 is the anti-HBs seropositive rate the before
booster, and PR2 is the response rate in the booster
recipients.
All of the seronegative subjects had received a booster
dose in the Wu et al. study [13]. Therefore, no booster
rate was needed in their formula. In our study, the
booster rate was defined as the percentage of seronega-
tive subjects receiving one booster dose. The response
rate was defined as the proportion of those booster reci-
pients whose post-booster anti-HBs titer was ≥10 mIU/mL.
Longitudinal study
In our database of the university-affiliated education sys-
tem, we found by birth cohort tracing, that some of our
subjects studied in our senior high school and then conse-
quently in our university. We decided to follow the subjects
of birth cohort 1993–1994 in the 18-year age group whohad received the recombinant HBV vaccine in infancy. In
this way, the effects of different vaccine type were elimi-
nated. If the subjects previously studied in our senior high
school (15-year age group, birth cohort 1993–1994), they
were grouped as “the same school”. Their serum data of
both anti-HBs and HBsAg were analyzed longitudinally to
trace the pattern of seroconversion and post-booster
change in this 3-year interval. The other subjects of the 18-
year age group from the 1993–1994 birth cohort were used
as the comparison group, which was labeled as “the others”.
No records of booster history in “the others” group was
available, therefore, an uncertain proportion of subjects in
this group may have received a booster dose after their
HBV vaccination in infancy. We hypothesize that median
value of anti-HBs before HBV booster among subjects in
birth cohort 1993–1994 in the 15-year age group could
serve as the baseline median value in the 18-year age group.
The actual median titers of anti-HBs in the 18-year age
group would be further decayed if a booster dose was not
given or natural exposure did not occur. In addition to the
seropositivity rate of anti-HBs and HBsAg, median values
of anti-HBs titers at 18 years of age were compared among
two groups, “the same school” versus “the others”, to iden-
tify if booster effects were present in our comparison group.
We aimed to identify any additional protective effect by in-
creasing the levels of anti-HBs titers by comparing the
HBsAg seropositivity rate between these two groups.
Serologic testing
All quantification of seromarkers of HBV infection was per-
formed by enzyme immunoassay (data prior to 2011/08/31,
VITROS ECiQ Immunodiagnostics system, Ortho Clinical
Diagnostics; data after 2011/09/01, Abbott Laboratories,
North Chicago, IL, USA). Reference concentrations from
the WHO were used as criteria values and the protective
level of anti-HBs was defined as ≥10 mIU/mL [3]. Subjects
who were positive for HBsAg were assumed to be hepa-
titis B carriers [14].
Statistical analysis
A Chi-square test was performed to identify the dif-
ferences in seropositivity rates, including anti-HBs and
HBsAg, median titers of anti-HBs, between different
ages, genders, and other subgroups. Statistically signifi-
cant differences were defined as p < 0.05. All of the sta-
tistical analyses were performed using SPSS software
(version 17.0; SPSS Inc., Chicago, IL, USA).
Results
Part I: epidemiological study
The study subjects of this epidemiological survey consisted
of 6950 individuals (2901 were male and 4049 were female),
all of whom were born after 1987, within the national in-
fant HBV vaccination era of Taiwan. There were 524, 450,
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age groups, respectively. The overall seropositivity rate of
anti-HBs and HBsAg was 44.3% and 1.2%, respectively, in
our study subjects. Figure 2 shows the trend of anti-HBs
seropositivity rate and median titers by different age group
and time frame. Table 1 shows a statistically significant dif-
ference between age and the seropositivity rate of anti-HBs,
with a declining rate from 6 years to 12 years of age, which
then rises through 18 years of age in our study (p < 0.001).
However, the age-specific pattern of HBsAg seropositivity
did not show any statistical significance (p = 0.154) with
aging. The median titers of anti-HBs also showed statistical
significance with a pattern similar to that observed for anti-
HBs seropositivity. To assess the possible effects of a short-
age of data within the 12-year age group from 2007 to
2012, we analyzed the seropositive rates of anti-HBs and
HBsAg in all four age groups within the same interval
(2004–2006). A similar age-related pattern of anti-HBs
seropositivity was noted with a statistically significant dif-
ference among all individuals (p < 0.001). We further
pooled the two younger and two older age groups (6–12 vs
15–18 years) for comparison, and the results showed a
similar pattern to the four age group comparison. As com-
pared with seroprevalence data of HBV markers by genders
of all subjects, female individuals had a significantly higher
anti-HBs seropositivity rate (p < 0.009) than male individ-
uals, but this was not mirrored by HBsAg (p = 0.439).
Part II: subgroup assessment
Comparison of HBV markers by different vaccine types
In this part of our study, we selected the subjects by
their birth cohort, grouping as plasma-derived and re-
combinant groups in two age groups. We compared theFigure 2 The trend of anti-HBs seropositivity rate and median titers b
seropositive rate by age (2004-2012). (B) The trend of median titer value ofseroprevalence of anti-HBs and HBsAg within the dif-
ferent vaccine types in these two age groups. Table 2
shows that the seropositivity rate of anti-HBs in the
plasma-derived subgroup was significantly higher in both
the 15- and 18-year age groups (p < 0.004 and 0.003,
respectively). The seropositivity rate of HBsAg in the
plasma-derived subgroup was also significantly higher in
the 18-year age group (p = 0.049), but not in the 15-year
age group (p = 0.129).
Immunogenicity response in booster recipients in the
15-year age group
Among 1054 subjects of birth cohort 1992–1997 in the 15-
year age group, 657 subjects (62.3%) demonstrating sero-
negativity for both anti-HBs and HBsAg were further rec-
ommended to receive one booster dose of recombinant
HBV vaccine (20 μg/dose). Table 3 shows that 570 (86.8%)
of these 657 double seronegative subjects received one
booster dose and the overall response rate among booster
recipients with post-booster titer ≥10mIU/mL was 92.5%
(529/570). The overall anti-HBs seropositivity rate before
one booster dose was 37.7% (397/1054), while the overall
anti-HBs seropositivity rate after one booster dose was
87.7%. The annual post-booster rate had a range of 83.4–
93.6% in the 1992–1997 birth cohort. The median titers of
anti-HBs before and after booster dose were 1.1 mIU/mL
and 545.5 mIU/mL, respectively.
Longitudinal study
Among 1294 subjects in the 18-year age group of the
1993–1994 birth cohort, only 38 (2.9%) subjects had
studied in our senior high school (15-year age group,
birth cohort 1993–1994), followed by attendance at oury different age group and time frame. (A) The trend of anti-HBs
anti-HBs by age (2007-2012).
Table 1 Demographics data and seroprevalence of hepatitis B virus (HBV) markers and titers
Age group 6 y/o 12 y/o 15 y/o 18 y/o 6-12 y/o 15-18 y/o
Item (n = 524) (n = 450) (n = 1464) (n = 4512) (n = 974) (n = 5976)
Gender
Male, n (%) 299(57.1) 205(45.6) 740(50.5) 1657(36.7) 504(51.7) 2397(40.1)
Female, n (%) 225(42.9) 245(54.4) 724(49.5) 2855(63.3) 470(48.3) 3579(59.9)
Age (Mean ± SD, yr) 6.5 ± 0.3 12.5 ± 0.3 15.5 ± 0.5 18.7 ± 0.7 9.3 ± 3.0 17.9 ± 1.5
Anti-HBs (+), n 332 142 574 2033 474 2607
(%, 95% CI) (63.4, 59.3-67.5) (31.6, 27.3-35.9) (39.2, 36.7-41.7) (45.1, 43.6-46.6) (48.7, 45.6-51.8) (43.6, 42.3-44.9)
Anti-HBs (−), n 192 308 890 2479 500 3369
(%, 95% CI) (36.6, 32.5-40.7) (68.4, 64.1-72.7) (60.8, 58.3-63.3) (54.9, 53.4-56.4) (51.3, 48.2-54.4) (56.4, 55.1-57.7)
P-value <0.001* 0.003*
Anti-HBs median titer 21.2 NA 3.9 4.8 21.2 4.6
P-value <0.001* <0.001*
HBsAg (+), n 1 7 16 56 8 72
(%, 95% CI) (0.2, 0.0-0.6) (1.6, 0.4-2.8) (1.1, 0.6-1.6) (1.2, 0.9-1.5) (0.8, 0.2-1.4) (1.2, 0.9-1.5)
HBsAg (−), n 523 443 1448 4456 966 5904
(%, 95% CI) (99.8, 99.4-100.0) (98.4, 97.2-99.6) (98.9, 98.4-99.4) (98.8, 98.5-99.1) (99.2, 98.6-99.8) (98.8, 98.5-99.1)
P-value 0.154 0.336
Note: Anti-HBs, antibody to HBV surface antigen; HBsAg, HBV surface antigen; y/o, year old; NA, not available; 95% CI, 95% confidence interval; Data are presented
as or n and percentage.
*p-value < 0.05 was considered statistically significant after test.




Plasma-derived Recombinant Total P-value
Items
15 y/o
N [birth cohort] 410 [1989–91] 886 [1993–97] 1296
anti-HBs (+), n 177 307 484
0.004*
(%, 95% CI) (43.2, 38.4-48.0) (34.7, 31.6-37.8) (37.3, 34.3-39.9)
anti-HBs (−), n 233 579 812
(%, 95% CI) (56.8, 52.0-61.6) (65.3, 62.2-68.4) (62.7, 60.1-65.3)
HBsAg (+), n 7 6 13
0.129
(%, 95% CI) (1.7, 0.4-3.0) (0.7, 0.2-1.2) (1.0, 0.5-1.5)
HBsAg (−), n 403 880 1283
(%, 95% CI) (98.3, 97.0-99.6) (99.3, 98.8-99.8) (99.0, 98.5-99.5)
18 y/o
N [birth cohort] 2575 [1987–91] 1295 [1993–94] 3870
anti-HBs (+), n 1184 529 1713
0.003*
(%, 95% CI) (46.0, 44.1-47.9) (40.8, 38.1-43.5) (44.3, 42.7-45.9)
anti-HBs (−), n 1391 766 2157
(%, 95% CI) (54.0, 52.1-55.9) (59.2, 56.5-61.9) (55.7, 54.1-57.3)
HBsAg (+), n 40 10 50
0.049*
(%, 95% CI) (1.6, 1.1-2.1) (0.8, 0.3-1.3) (1.3, 0.9-1.7)
HBsAg (−), n 2535 1285 3820
(%, 95% CI) (98.4, 97.9-98.9) (99.2, 98.7-99.7) (98.7, 98.3-99.1)
Note: anti-HBs, antibody to HBV surface antigen; HBsAg, HBV surface antigen; y/o, year old; Data are presented as or n and percentage.
*p-value < 0.05 was considered statistically significant after test.
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Table 3 Booster response rate and change of overall anti-HBs seropositive rate before and after one booster dose
Year Seroprevalence, n (%) Subjects, n (%) Post-booster Anti-HBs titer (median)
[birth cohort] Anti-HBs (+) Anti-HBs (−) Booster rate Response rate Anti-HBs (+) Before After
2007 [1992] 90 (53.6) 78 (46.4) 66 (84.6) 55 (83.3) 86.3%
2.1 ± 2.3 399.4 ± 394.0
(P50 = 1.4) (P50 = 288.5)
2008 [1993] 67 (39.4) 103 (60.6) 90 (87.4) 75 (83.3) 83.5%
1.7 ± 2.1 480.7 ± 423.4
(P50 = 0.7) (P50 = 365.5)
2009 [1994] 85 (49.4) 87 (50.6) 76 (87.4) 77 (100.0) 93.6%
1.5 ± 2.2 678.4 ± 385.5
(P50 = 0.3) (P50 = 975.0)
2010 [1995] 61 (35.1) 113 (64.9) 96 (85.0) 85 (87.6) 83.4%
2.7 ± 2.0 540.2 ± 421.2
(P50 = 2.3) (P50 = 556.5)
2011 [1996] 40 (23.7) 129 (76.3) 112 (86.8) 111 (99.1) 89.3%
1.2 ± 2.0 589.3 ± 377.2
(P50 = 0.2) (P50 = 555.4)
2012 [1997] 54 (26.9) 147 (73.1) 130 (88.4) 126 (96.9) 89.5%
2.6 ± 2.8 579.2 ± 387.7
(P50 = 1.7) (P50 = 573.7)
Total 397 (37.7) 657 (62.3) 570 (86.8) 529 (92.5) 87.7%
2.0 ± 2.3 551.5 ± 403.6
(P50 = 1.1) (P50 = 545.5)
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1256 (97.1%) subjects of the 18-year age group within
the same birth cohort were labeled as “the others”, mea-
ning they graduated from another senior high school with
unclear booster status. Figure 3 shows that the anti-HBs
seropositivity rate of these 38 subjects in “the same school”
group at 15 years of age was 31.6% (12/38), while 68.4%
(26/38) of them demonstrated double seronegativity of
anti-HBs/HBsAg at this age. Among 26 double seronega-
tive subjects, 96.2% (25/26) received one booster dose of
HBV vaccine at age 15 years. The response rate at 6 weeksFigure 3 Change of hepatitis B virus (HBV) seromarkers follow up forafter the HBV booster among these 25 recipients was
96.0% (24/25). The overall anti-HBs seropositivity rate for
all “the same school” subjects at 6 weeks and 3 years after
one booster dose was 94.8% and 76.3%, respectively.
Among the 24 recipients showing anti-HBs seroconversion
at 6 weeks after booster, seven subjects (29.2%) had lost
their anti-HBs seropositivity again within 3 years. The lone
double seronegative subject in “the same school” group
who did not receive a booster (1/26) retained her double
seronegative status for the duration of the 3-year follow-up
interval. For those 12 subjects with anti-HBs seropositive3-year after HBV booster.
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retained anti-HBs seropositivity after 3 years.
We also compared the 38 subjects of “the same school”
group with 1256 subjects of “the others” group from the
birth cohort 1993–1994 in the 18-year age group to deter-
mine if higher rates of anti-HBs seropositivity did indeed
provide better protection against HBV infection. Table 4
shows that the seropositivity rates of anti-HBs among “the
same school” group versus “the others” group were 76.3%
and 39.7%, respectively (p < 0.001). Median titers of anti-
HBs were also shown to be significantly different between
these two groups (i.e., 24.7 vs 4.2 mIU/mL, in “the same
school” and “the others”, respectively, p <0.001). There were
no new cases of HBsAg seropositivity in “the same school”
group, and the seroprevalence rate of HBsAg was 0.8% in
“the others” group.
Discussion
In previous studies conducted in Taiwan, the seropositivity
rate of anti-HBs declined from 99% at 1 year of age to
83% at 5 years of age [15] and further dropped to 71.1% at
7 years of age, 37.4% at 12 years of age and 37% at 15–17
years of age [16]. The HBsAg seropositivity rate in chil-
dren less than 12 years of age decreased from 9.8% in
1984 to 1.3% in 1994. The seropositivity rate of anti-HBc
also decreased from 26% in 1984 and 15% in 1989 to 4%
in 1994 [1]. In a 2004 survey, Ni et al. showed that the
anti-HBc seropositivity rate was low (1%) in children less
than 15 years of age [7]. In 2004, the seropositivity rates
for HBsAg, anti-HBs, and anti-HBc were 1.2%, 50.5%, and
3.7%, respectively, in those born after implementation of
the vaccination program (age <20 years) [7].
In our study, the overall seropositivity rates of HBsAg
and anti-HBs were 1.2% and 43.6%, respectively, in those
individuals less than 18 years of age. In Table 1, we noted
a phenomenon in which the seropositivity rate of anti-
HBs decayed from 63.4% (age 6 years) to 31.6% (age
12 years) and then increased from 12 to 18 years of age.
To the best of our knowledge, there is no research report-
ing a phenomenon similar to the data presented in
Figure 2. Reactivation effects (HBV vaccine booster),
natural boosters (boosting of the anti-HBs titer after aTable 4 Comparison of seroprevalence of HBsAg and anti-HB
Item
The same school (n =
Anti-HBs (+), n (%, 95% CI) 29 (76.3, 62.8-89.8)
Anti-HBs (−), n (%, 95% CI) 9 (23.7, 10.2-37.2)
Anti-HBs titer, mean ± SD (median) 157.6 ± 281.3 (P50 = 24
HBsAg (+), n (%) 0 (0.0)
HBsAg (−), n (%) 38 (100.0)
Data are presented as n and percentage or mean ± standard deviation (median).
*p-value < 0.05 was considered statistically significant after test.natural exposure), and breakthrough infections (having
HBV infection despite receiving three or more doses of
HBV vaccine) could all contribute to the pattern of in-
crease in anti-HBs from 12 to 18 years of age as observed
in this study. Tracing our subjects by their birth cohort
(1992–1994) in the 12-year age group, we found 110 sub-
jects (110/510, 21.6% of total enrolled students of senior
high school in the corresponding period) had also enrolled
in our senior high school at 15 years of age. Of subjects
with seronegative anti-HBs titers at 12 years of age, 78.8%
(63/80) were found to be seropositive at age 15 years (data
not shown). We were unable to trace their booster records
individually, although such seroconversion was highly in-
dicative of booster effects, which may be a factor that in-
terfered with the anti-HBs seropositivity rate in this birth
cohort in the 15-year age group. Similarly, booster effects
might also contribute to the elevated seropositivity rate
and median titers of anti-HBs in the 18-year age group
with less amplitude of influence if compared with those
values in the 15-year age group.
In previous studies, the anti-HBc positivity rate of ele-
mentary school first graders within the 3-year follow-up
period (2005–2007, birth cohort 1999) was between 1 and
2% in the North, Central, and South of Taiwan but was
higher (3.5–4.8%) in Eastern Taiwan [17]. Another survey
conducted in 2004 among children younger than 18 years
of age in Taiwan showed breakthrough HBV infection was
about 1% in children sampled (136/13765) [7]. Therefore,
the unique phenomenon of increasing anti-HBs sero-
positivity rate after 12 years of age was likely because of
booster reactivation effects. Poovorawan et al. reported
that breakthrough infections during the first decade after
primary vaccination in infancy were only observed in chil-
dren born to high-risk families (maternal seropositive for
both HBsAg and HBeAg). In the second decade after pri-
mary vaccination, breakthrough infections were detected
in 12.9% of individuals, possibly reflecting increased ex-
posure outside the home, linked to high-risk adolescent
behaviors [18].
The highest rate of HBsAg seropositivity was 1.6% in
the 12-year age group of this study, but no statistical
significance (p = 0.154) was observed in the pattern ofs in “the same school” and “the others” groups
18-year age group (birth cohort 1993–1994)
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year age group were born between 1992 and 1994 and
their HBsAg seropositivity rate was consistent with other
studies within the same time frame [17]. Natural HBV
infections (positive for anti-HBc) and HBV carriers
(seropositive HBsAg) were found in 4.1% and 1.6% of in-
dividuals, respectively, at 15–17 years of age in a post-
1986 cohort in Taiwan [10].
Based on data from previous studies, different types of
HB vaccines, doses, and brands as well as the timing of
primary vaccination can all influence the persistence of
anti-HBs titers [19]. In Taiwan, neonates born before
July 1992 received four doses of plasma-derived vaccine
(Hevac B; Pasteur-Merieux, or its equivalent derivative);
neonates born after July 1992 received recombinant
HBV vaccines (5 μg/dose of Recombivax [Merck] or
20 μg/dose of Engerix [GSK]) instead. In Table 2, we
demonstrate that individuals in the plasma-derived sub-
group had a higher proportion of positivity for anti-HBs
than did those of the recombinant subgroup in both the
15- and 18-year age groups (43.2% vs 34.7% at 15 years,
p < 0.004; 46.0% vs 40.8% at 18 years, p < 0.003). Our
finding is consistent with several other studies [20,21].
The seropositivity rate of HBsAg in the plasma-derived
subgroup is significantly higher than that of the recom-
binant subgroup in the 18-year age group (p = 0.049)
alone, but not in the 15-year age group (p = 0.131). In
our subsequent study, only the subjects who received re-
combinant HBV vaccine were pooled together for a
longitudinal study to avoid the interference of different
vaccine type and dosage given in infancy.
According to the birth cohort (1987–2003) analysis for
long-term immunity following infant HBV vaccination, no
increase of the seropositivity rates of HBsAg and anti-HBc
was noted after 17 years of age [7]. In contrast, 15–50% of
the children who initially responded to the three-dose
series of HBV vaccination had low or undetectable anti-
HBs levels 5–15 years after primary vaccination [8]. Wu
et al. reported that the overall anti-HBs seropositivity rate
after a booster dose of HB vaccine was estimated to be
84.3% among 1974 students from senior high schools with
negative titers of both anti-HBs and HBsAg before the HB
vaccine booster [13]. Long-term protection studies indi-
cated that immunological memory usually persisted even
if anti-HBs levels fell below the protective threshold
(10 mIU/mL) [20,21]. However, without protective levels
of anti-HBs, memory cells alone are probably unable to
protect against acute infection [22]. In our subjects within
the 15-year age group from the birth cohort 1992–1997
presented in Table 3, booster response rate was 92.5%
(529/570) after one booster dose of recombinant HBV
vaccine (20 μg/dose). Anti-HBs seropositivity rate before
one booster dose was 37.7% (397/1054) and became 87.7%
afterwards. The median titers of anti-HBs before and afterbooster dose were 1.1 mIU/mL and 545.5 mIU/mL, re-
spectively. All the subjects received recombinant HBV
vaccine in their neonatal period, except the individuals
from the 1992 birth cohort, who received plasma-derived
HBV vaccine if they were born before July 1992. Lu et al.
showed the booster response rate to one dose of recom-
binant HBV vaccine was 71% in 15- to 17-year-old sub-
jects who received plasma-derived HBV vaccine during
neonatal immunization [10]. All the subjects from the Wu
et al. [13] study were born between July 1987 and July
1991 and thus belonged to the plasma-derived HBV
vaccine era in Taiwan. Therefore, the booster response
pointed to the recipients who received the plasma-derived
vaccine in infancy.
In Figure 3, we selected and followed 38 subjects who
had graduated from our senior high school and con-
sequently studied in our university. We monitored the
changes in the seropositivity rates of anti-HBs and HBsAg
within a time frame of 3 years. We found that the initial
booster response rate at 6 weeks after one booster dose of
HBV vaccine was as high as 96% (24/25) in our 15-year-
old subjects. Surprisingly, seven subjects (29.2%, 7/24
booster responders) who became seropositive after their
booster dose lost their anti-HBs seropositivity again within
3 years after booster. The overall anti-HBs seropositivity
rate for all “the same school” subjects at 6 weeks and
3 years after one booster dose was 94.8% and 76.3%,
respectively. For the comparison group labeled as “the
others”, subjects from the same birth cohort in the
18-year age group, the seropositivity rates of anti-HBs and
HBsAg were 39.7% (499/1256) and 0.8% (10/1256), re-
spectively. The median titer of subjects in “the others”
group was 4.2 mIU/mL (24.7 mIU/mL in “the same
school”). During the 3-year follow-up period, no new
HBV carriers were detected in “the same school” group,
which included students given a booster dose if their anti-
HBs titers were seronegative. However, there was no sta-
tistical difference (p = 0.581) in HBV carrier rate between
“the same school” subgroup and “the others” subgroup
(0% vs 0.8%, respectively). An HBsAg seropositivity rate of
0.8% at 18 years of age in our study group was comparable
to the seroprevalence of the same age group in other
studies [7]. In our study, booster vaccination did not con-
fer additional protection against HBsAg carriage. High
booster response rate (96%) at 6 weeks after one booster
dose at 15 years of age also indicated intact long-term pro-
tection of HBV infection by immunological memory, as a
result of anamnestic response after primary infant HBV
vaccination. Immunity against HBV provided protection
against infection as well as against disease. Protection
against infection is associated with antibody persistence,
which is directly related to the peak production of anti-
HBs after primary vaccination. Protection against disease
(i.e., acute hepatitis, prolonged viraemia, carriership, and
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persists beyond the time at which anti-HBs disappears [9].
Currently, Middleman et al. show several variables inde-
pendently associated with higher geometric mean titer re-
sponse to a challenge dose of vaccine included a higher
baseline anti-HBs titer, older age at first dose of primary
series (≥4 weeks after birth), higher test dosage, and non-
white race [23]. In contrast to the high endemicity of HBV
in Taiwan, Middleman et al. collected these new data re-
garding duration of protection in the setting of low hepa-
titis B endemicity in the United States, with a likely
absence of natural boosting. The response to the challenge
dose of HB vaccine was remarkably good, as high as 92%
[23], which is similar to our booster response rate after
one booster dose of HBV vaccine at 15 years of age.
Taking Taiwan as an example of an HBV endemic
area, the seropositivity rates of HBsAg and HBeAg for
pregnant women were still 10.3% and 2.3% in 2009 (data
from Taiwan Centre for Disease Control, Department of
Health). Additionally, the mean age of mothers giving
birth in 2007–2009 was 29.45 years of age, which meant
the majority were born after the introduction of infant
HBV vaccination. Horizontal and breakthrough infection
could also occur after waning or eventual loss of the
vaccine protectiveness in older children, especially with
changes in lifestyle and sexual activity [9]. A concern ex-
ists about sexual exposure to HBsAg carriers in hyperen-
demia areas such as Taiwan when vaccinated children
become adolescents and young adults. Ni et al. showed
no increase in seropositivity rates of either HBsAg or
anti-HBc when vaccinated individuals progressed to
17 years of age [7] and the rate of chronicity declined as
the age of infection increased: 25% in infected preschool
children and 3–10% in adolescents and young adults
[24]. Although universal booster dose may not be neces-
sary up to 20 years after the primary vaccination because
HBsAg and anti-HBc seropositivity did not increase [7],
the methods for the prevention of horizontal transmission,
such as avoidance of skin tattooing, use of disposable nee-
dles, and condom use in sexual contact still need continu-
ous implementation in the adolescent group [25]. Based
on our data, the current guidelines from Taiwan Advisory
Committee on Immunization Practice (ACIP) appear to
be adequate, and states that individuals may receive a
booster dose if they have negative anti-HBs antibodies and
are in high-risk groups (i.e., hemodialytic, organ trans-
plant, and immunocompromised patients; intravenous
drug users; participants in high-risk sexual activity; or
health care workers).
The major limitations of our study were as follows. First,
the retrospective cross-sectional study design and records
analysis was conducted without reviewing any vaccination
records for all subjects. Second, quantitative data of anti-
HBs titers were available for all four age groups in theperiod of 2007–2012 but anti-HBc was not routinely
screened for during entrant health-screening examination
owing to a decreased seropositivity rate of this marker
[26,27] and a high proportion of HBV-DNA negativity in
anti-HBc positive subjects [28]. As a result, the seroposi-
tivity rates of natural infection could not be estimated in
our study. Third, despite achievement of high HBV vac-
cine coverage rates from 88.8% to 96.9% (from 1984 to
2010) according to data from the Centre for Disease Con-
trol in Taiwan [11,12], there was a possible bias in primary
versus booster doses in our study subjects. The proportion
of booster rate in “the others” subgroup analysis could not
be identified and therefore we could only state possible
booster dose effects according to the level of anti-HBs
titers when comparing these data to the value of anti-HBs
in subjects from the same birth cohort.
Conclusions
HBV booster strategy at 15 years of age was the main
contributor to the unique age-related phenomenon of
anti-HBs seropositive rate and titers. No increase in
HBsAg seropositivity rates within different age groups
(p = 0.154) was observed. Female individuals demon-
strated significantly higher anti-HBs seropositivity com-
pared with male individuals (p < 0.015). Vaccination with
plasma-derived HBV vaccines in infancy provided a
higher rate of anti-HBs seropositivity at 15–18 years of
age in our study than the recombinant vaccine. The
overall response rate at 6 weeks after one HBV booster
dose was 92.5% in subjects demonstrating double sero-
negativity for anti-HBs and HBsAg, which indicated that
intact immunogenicity persisted at least 15 years after
primary infant HBV vaccination. Booster vaccination of
HBV did not confer additional protection against HBsAg
carriage in our study. Therefore, based on our data, we
conclude that the current booster strategy implemented
by Taiwan ACIP, which states that individuals may re-
ceive a booster dose if they have negative anti-HBs anti-
bodies and are in high-risk groups (i.e., hemodialytic,
organ transplant, and immunocompromised patients;
intravenous drug users; participants in high-risk sexual
activity; or health care workers), remains adequate.
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